Constellation Pharmaceuticals Inc (CNST)
In a report released yesterday, Leah R. Cann from Oppenheimer assigned a Buy rating to Constellation Pharmaceuticals Inc, with a price target of $21. The company’s shares closed yesterday at $6.09, close to its 52-week low of $5.57.
“Loss per share of $0.81 was higher than our estimated $(0.49). Net loss was 30.7% higher than our estimated net loss of $12.2 million due to higher than estimated R&D and SG&A. We are increasing estimated operating expenses and loss per share for 2018. Our outlook for 2019 – 2025 is basically unchanged.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 5.4% and a 41.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Currently, the analyst consensus on Constellation Pharmaceuticals Inc is a Strong Buy with an average price target of $19.
Catalyst Pharma (CPRX)
In a report released yesterday, Leland Gershell from Oppenheimer reiterated a Buy rating on Catalyst Pharma, with a price target of $6. The company’s shares closed yesterday at $3.08.
“3Q net loss per share of $0.08 was in line with our est. We are just under three weeks away from Firdapse’s 11/28/18 PDUFA date, for which we continue to expect FDA approval in LEMS. On its call, mgmt gave color on launch-readiness, including commercial team buildout, patient support services, and EAP conversion effort. Phase 3 data in CMS and MuSK-MG, indications for which Firdapse has demonstrated clear signs of efficacy, are expected in 2H19 and each could enable a respective label expansion. We forecast ~$500M in peak 2025E sales of Firdapse in LEMS/CMS alone, with MuSK-MG representing an incremental $150-200M revenue opportunity. We recommend purchase heading into Firdapse’s potential approval and launch.”
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -1.8% and a 36.8% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and AzurRx BioPharma Inc.
Currently, the analyst consensus on Catalyst Pharma is a Strong Buy with an average price target of $6.60, an 114.3% upside from current levels. In a report issued on October 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $8 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CPRX:
- Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst
- Oppenheimer Pounds the Table on Catalyst Pharmaceuticals (CPRX) Ahead of Upcoming FDA Decision
- Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)
- Cantor Sees Strong Upside in Catalyst Pharmaceuticals (CPRX) Shares, Sets an $8 Price Target